Skip to content

Nevirapine Resistance Study: Nevirapine Resistance Among HIV-Infected Mothers

Nevirapine Pharmacodynamics and Resistance Among HIV-Infected Mothers in Lilongwe, Malawi

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00164762
Enrollment
126
Registered
2005-09-14
Start date
2005-06-30
Completion date
2006-11-30
Last updated
2007-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

HIV, drug resistance, nevirapine, anti-retroviral drugs, mother-to-child transmission, Treatment Naive, pregnancy

Brief summary

The purpose of this study is to determine whether the addition of zidovudine (ZDV) and lamivudine (3TC) at the onset of labor and for up to seven days postpartum to single-dose nevirapine (NVP) is associated with a lower prevalence of NVP-resistant HIV compared to single-dose NVP without ZDV+3TC.

Detailed description

The primary purpose of the Nevirapine Resistance Study is to compare nevirapine (NVP) resistance of HIV at two and six weeks postpartum in women who are participating in two different programs currently ongoing in Lilongwe, Malawi. The first program is through the HIV Infection and Breastfeeding: Interventions for Maternal and Infant Health, also known as the Breastfeeding, Antiretrovirals and Nutrition (BAN) Study, a clinical trial where all enrolled women receive zidovudine (ZDV) and lamivudine (3TC) at the onset of labor and for up to seven days postpartum in addition to single-dose nevirapine (NVP). The second program is the Call to Action (CTA) program sponsored by the Malawi Ministry of Health and Population (MOHP) and UNC Project. The aim of the CTA program is to reduce mother to child transmission (MTCT) of HIV by providing women a single dose NVP to be taken at the onset of labor. Study participants are tested for NVP-resistant HIV at two and six weeks postpartum and the prevalence of NVP-resistant virus is compared among the two groups receiving different peripartum anti-retroviral regimens.

Interventions

None listed

Sponsors

Kamuzu Central Hospital
CollaboratorOTHER
University of North Carolina
CollaboratorOTHER
Centers for Disease Control and Prevention
Lead SponsorFED

Study design

Observational model
DEFINED_POPULATION
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* HIV infected * CD4 count \> 200 cells/μL * ALT \< 2.5 x upper limit of normal (ULN) * Hemoglobin (Hb) \> 7 g/dL * Age \> 18 years, or \<18 years and married (considered emancipated minors in Malawi) * Ability to give informed consent * Evidence of HIV infection, as documented by 2 positive Enzyme-Linked Immunosorbent Assays (ELISA's); or 1 positive ELISA, and 1 Western blot (WB); or 2 separate concurrent rapid tests. These are the World Health Organization (WHO) acceptable criteria for diagnosing HIV-1 infection in adults. * Currently pregnant (with a single or multiple fetuses) * Gestation \< 34 weeks * No serious current complications of pregnancy * Intention to breastfeed * Intention to deliver at the institution in which the study is based * Other than HIV, no active serious infection, such as tuberculosis or other potentially serious illnesses * No previous use of antiretrovirals including the HIVNET 012 regimen

Countries

Malawi

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 27, 2026